<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531932</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 15-1075</org_study_id>
    <nct_id>NCT02531932</nct_id>
  </id_info>
  <brief_title>Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer</brief_title>
  <official_title>A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amy Tiersten</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of carboplatin compared&#xD;
      to the combination of carboplatin and everolimus for the treatment of advanced&#xD;
      triple-negative breast cancer (TNBC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival (PFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time from the date of randomization to confirmed disease progression or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Overall Response by RECIST 1.1. the best response recorded from the start of the study treatment until the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The time from the date of randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The best overall response rate including complete response (CR) + partial response (PR) + stable disease (SD) &gt;= 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Carboplatin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AUC 4 every 3 weeks as an IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carboplatin + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 4 every 3 weeks IV infusion plus daily oral everolimus 5mg pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin will be administered if ANC &gt; 1.0 and platelets are &gt;75k</description>
    <arm_group_label>Carboplatin + Everolimus</arm_group_label>
    <arm_group_label>Carboplatin alone</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>The study drug Everolimus will be self-administered (by the patients themselves).</description>
    <arm_group_label>Carboplatin + Everolimus</arm_group_label>
    <other_name>Certican®</other_name>
    <other_name>Zortress®</other_name>
    <other_name>Votubia®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with metastatic breast cancer (measurable or evaluable including bone metastases&#xD;
             only)&#xD;
&#xD;
          -  Histologically confirmed triple negative breast cancer (ER&lt; 10%, PR &lt; 10%, Her2neu IHC&#xD;
             0 or 1 or FISH/ISH negative)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  WHO performance status ≤ 2&#xD;
&#xD;
          -  Adequate bone marrow function as shown by: ANC ≥ 1.5 x 10^9/L, Platelets ≥ 75 x&#xD;
             10^9/L, Hb &gt;9 g/dL&#xD;
&#xD;
          -  Adequate liver function as shown by:&#xD;
&#xD;
               -  serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  ALT and AST ≤ 2.5x ULN (≤ 5x ULN in patients with liver metastases)&#xD;
&#xD;
          -  Adequate renal function: serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients may have had up to 3 prior regimens for metastatic disease&#xD;
&#xD;
          -  A baseline CT chest/abdomen/pelvis and bone scan or PET/CT&#xD;
&#xD;
          -  Negative serum pregnancy test within 7 days prior to starting treatment&#xD;
&#xD;
          -  Stable brain metastases allowed (&gt; 2 weeks, clinically-stable post treatment with&#xD;
             surgery+/-radiation or radiation alone and off steroids)&#xD;
&#xD;
          -  Prior carboplatin allowed provided greater than 12 mos have elapsed since last dose of&#xD;
             carboplatin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients currently receiving anticancer therapies or who have received anticancer&#xD;
             therapies within 2 weeks of the start of study drug (including chemotherapy, radiation&#xD;
             therapy, and biologics)&#xD;
&#xD;
          -  Patients, who have had a major surgery or significant traumatic injury within 4 weeks&#xD;
             of start of study drug, patients who have not recovered from the side effects of any&#xD;
             major surgery (defined as requiring general anesthesia) or patients that may require&#xD;
             major surgery during the course of the study&#xD;
&#xD;
          -  Prior treatment with any investigational drug within the preceding 2 weeks&#xD;
&#xD;
          -  Patients receiving chronic, systemic treatment with corticosteroids or another&#xD;
             immunosuppressive agent, except corticosteroids with a daily dosage equivalent to&#xD;
             prednisone ≤ 20 mg. However, patients receiving corticosteroids must have been on a&#xD;
             stable dosage regimen for a minimum of 4 weeks prior to the first treatment with&#xD;
             Everolimus. Topical or inhaled corticosteroids are allowed.&#xD;
&#xD;
          -  Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole,&#xD;
             ritonavir) or P-glycoprotein (PgP) is prohibited. Co-administration with moderate&#xD;
             CYP3A4 inhibitors (e.g., erythromycin, fluconazole) or PgP inhibitors may be used with&#xD;
             caution and everolimus dosing must be discussed with PI at the time of enrollment. For&#xD;
             a current table of Substrates, Inhibitors and Inducers please access the following&#xD;
             website:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/&quot;&#xD;
&#xD;
          -  Patients who have received live attenuated vaccines within 1 week of start of&#xD;
             Everolimus and during the study. Patient should also avoid close contact with others&#xD;
             who have received live attenuated vaccines. Examples of live attenuated vaccines&#xD;
             include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever,&#xD;
             varicella and TY21a typhoid vaccines&#xD;
&#xD;
          -  Uncontrolled brain metastases&#xD;
&#xD;
          -  Leptomeningeal metastases&#xD;
&#xD;
          -  Other malignancies within the past 3 years except for adequately treated carcinoma of&#xD;
             the cervix or basal or squamous cell carcinomas of the skin.&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study such as:&#xD;
&#xD;
               -  Symptomatic congestive heart failure of New York heart Association Class III or&#xD;
                  IV&#xD;
&#xD;
               -  unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction within 6 months of start of study drug, serious uncontrolled cardiac&#xD;
                  arrhythmia or any other clinically significant cardiac disease&#xD;
&#xD;
               -  severely impaired lung function as defined as spirometry and DLCO that is 50% of&#xD;
                  the normal predicted value and/or 02 saturation that is 89% or less at rest on&#xD;
                  room air&#xD;
&#xD;
               -  uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 x ULN&#xD;
&#xD;
               -  active (acute or chronic) or uncontrolled severe infections&#xD;
&#xD;
               -  liver disease such as cirrhosis, chronic active hepatitis or chronic persistent&#xD;
                  hepatitis Note: A detailed assessment of Hepatitis B/C medical history and risk&#xD;
                  factors must be done at screening for all patients. HBV DNA and HCV RNA PCR&#xD;
                  testing are required at screening for all patients with a positive medical&#xD;
                  history based on risk factors and/or confirmation of prior HBV/HCV infection. See&#xD;
                  Appendix I (Hep Screening Form)&#xD;
&#xD;
          -  A known history of HIV seropositivity&#xD;
&#xD;
          -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of Everolimus (e.g., ulcerative disease,&#xD;
             uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel&#xD;
             resection)&#xD;
&#xD;
          -  Patients with an active, bleeding diathesis&#xD;
&#xD;
          -  Patients who have received prior treatment with an mTOR inhibitor (sirolimus,&#xD;
             temsirolimus, everolimus).&#xD;
&#xD;
          -  Patients with a known hypersensitivity to Everolimus or other rapamycins (sirolimus,&#xD;
             temsirolimus) or to its excipients&#xD;
&#xD;
          -  Patients with a known hypersensitivity to carboplatin&#xD;
&#xD;
          -  History of noncompliance to medical regimens&#xD;
&#xD;
          -  Patients unwilling to or unable to comply with the protocol&#xD;
&#xD;
          -  Ongoing alcohol or drug addiction&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential who are not using effective birth control methods. If barrier contraceptives&#xD;
             are being used, these must be continued throughout the trial by both sexes. Hormonal&#xD;
             contraceptives are not acceptable as a sole method of contraception. (Women of&#xD;
             childbearing potential must have a negative urine or serum pregnancy test within 7&#xD;
             days prior to administration of Everolimus)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Tiersten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Tiersten, MD</last_name>
    <phone>212-824-8591</phone>
    <email>amy.tiersten@mssm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mount Sinai Downtown</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MD</last_name>
    </contact>
    <investigator>
      <last_name>Paula Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai West</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anupama Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amy Tiersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2015</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Amy Tiersten</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>advanced triple negative breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

